Avoid co-administration of pralsetinib with strong or moderate CYP3A inhibitors, P-gp inhibitors, or agents that are both P-gp inhibitors and strong/moderate CYP3A inhibitors. If co-administration cannot be avoided, the dose of pralsetinib should be reduced. Avoid co-administration of pralsetinib with strong or moderate CYP3A inducers. If co-administration cannot be avoided, the dose of pralsetinib should be increased.
from FDA,2024.03
During treatment with pralsetinib, it is imperative that you inform your healthc···【more】
Release date:2026-01-16Recommended:26
While certain medications should not be used together at all, in other cases, tw···【more】
Release date:2026-01-16Recommended:27